ExodusPoint Capital Management’s iTeos Therapeutics ITOS Stock Holding History

ExodusPoint Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-64,368	Closed	-$384K	–	1712
2025 Q1	$384K	Sell	64,368 -23,819	-27%	-$175K	﹤0.01%	1169
2024 Q4	$677K	Buy	+88,187	New	+$758K	﹤0.01%	1066
2024 Q3	–	Sell	-37,673	Closed	-$559K	–	1836
2024 Q2	$559K	Buy	37,673 +21,517	+133%	+$308K	﹤0.01%	1193
2024 Q1	$220K	Sell	16,156 -47,394	-75%	-$516K	﹤0.01%	1328
2023 Q4	$696K	Buy	63,550 +41,555	+189%	+$412K	﹤0.01%	943
2023 Q3	$241K	Buy	21,995 +6,577	+43%	+$84.1K	﹤0.01%	1475
2023 Q2	$204K	Buy	+15,418	New	+$220K	﹤0.01%	1672
2022 Q2	–	Sell	-25,325	Closed	-$815K	–	2170
2022 Q1	$815K	Sell	25,325 -56,186	-69%	-$2.04M	0.01%	1274
2021 Q4	$3.79M	Buy	+81,511	New	+$2.71M	0.04%	530

Other funds holding ITOS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ExodusPoint Capital Management's ITOS Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 64,368 shares — an estimated $384K sold.

ExodusPoint Capital Management first reported a position in ITOS in Q4 2021 and held it in 9 quarters. The position peaked at $3.79M in Q4 2021. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

ExodusPoint Capital Management reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 64,368 iTeos Therapeutics shares in Q2 2025, an estimated $384K.
ExodusPoint Capital Management first reported a position in iTeos Therapeutics in Q4 2021 and held it in 9 quarters.
ExodusPoint Capital Management's iTeos Therapeutics position peaked at $3.79M in Q4 2021.
136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.